Neurocrine Biosciences to Present at the Stifel 2023 CNS Days

Neurocrine Biosciences (NASDAQ: NBIX) will present at the Stifel 2023 CNS Days on Tuesday, March 28, 2023, at 12:30 p.m. Eastern Time.

Rhea-AI Summary

Neurocrine Biosciences (NASDAQ: NBIX) will present at the Stifel 2023 CNS Days on Tuesday, March 28, 2023, at 12:30 p.m. Eastern Time. Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will represent the company.

The live presentation will be webcasted and can be accessed on Neurocrine's website under the Investors section. A replay of the event will be available about one hour after the presentation and archived for one month.

Argus Session date unavailable

-1.34% session move Open Argus

Details

News Market Reaction – NBIX

The recorded move for NBIX in the trading session of this news was -1.34%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 21, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2023 CNS Days at 12:30 p.m. Eastern Time on Tuesday, March 28, 2023. Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will participate at the conference.       

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid- to late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, Twitter, and Facebook. (*in collaboration with AbbVie)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-stifel-2023-cns-days-301776917.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What time will Neurocrine Biosciences present at the Stifel 2023 CNS Days?

Neurocrine Biosciences will present at 12:30 p.m. Eastern Time on Tuesday, March 28, 2023.

Who from Neurocrine Biosciences will participate in the Stifel 2023 CNS Days?

Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will participate.

Where can I access the live presentation for Neurocrine Biosciences?

The live presentation can be accessed on Neurocrine's website under the Investors section.

How long will the replay of the Neurocrine Biosciences presentation be available?

The replay will be available for approximately one month after the presentation.

What is the stock symbol for Neurocrine Biosciences?

The stock symbol for Neurocrine Biosciences is NBIX.